As the 4 July looms on the horizon, experts say that the UK clinical trial landscape could be due for a significant makeover.
Ahead of a nationwide election, major UK political parties have promised ways to revamp the healthcare system. The Labour party has proposed measures to establish a maximum of 18 weeks from referral to consultant-led treatment of non-urgent health conditions amongst other actions. On the other hand, the Conservative party has pledged to increase National Health Service (NHS) spending above inflation each year. However, alongside the broader healthcare policies, the UK鈥檚 pharmaceutical and clinical trials industry also stands to experience change.
Last year, the former health minister, Lord James O鈥橲haughnessy led a review of the UK commercial clinical trial landscape that outlined major areas for improvement. After the review, the government set forth aims to tackle O鈥橲haughnessy鈥檚 recommendations already making some major progress towards some of the review鈥檚 goals.
In such a backdrop, experts at the Annual Outsourcing in Clinical Trials UK and Ireland conference in London, held earlier this month, debated ways to improve the UK鈥檚 standing in the global clinical research market, amidst conversations about artificial intelligence (AI), clinical trials in the APAC region, and more.
UK Clinical landscape
At the conference, Dr. Andrew Ustianowski, the network director at the National Institute for Health and Care Research鈥檚 (NIHR) North West Regional Research Delivery Network, highlighted the Vaccine Innovation Pathway鈥檚 March 2024 launch of a funding call, and clearance of the MHRA backlog as significant steps forward. He reported that, as of May 2024, 79% of open UK clinical studies were 鈥渄elivering to time and target鈥�. However, he called attention to new important areas of improvement.
Ustianowski said that the UK needs to boost the speed of its timelines for clinical trial approval to catch up to international standards. O鈥橲haughnessy highlighted that statistics show that UK clinical trials are carried out twice as slow as the US trials, and a third slower than those in Australia and Spain. Moreover, sponsors make their regulatory submissions to the UK later than other countries, added Ustianowski. O鈥橲haughnessy offered the potential solution of evaluating the functionality of the current framework against those of other countries. He said that the UK commonly approaches appraisals of its system through comparison to previous versions.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAPAC鈥檚 potential as a clinical hub
The conference also highlighted rising trends in the clinical trial landscape towards therapeutic development in the Asia-Pacific (APAC) region. A presentation from Scotty Chung-Siu, a GlobalData managing analyst, reported that the APAC region is leading the clinical development of adoptive cell therapies. GlobalData reports that there are 1,072 ongoing adoptive cell therapy trials in the APAC region, compared to 569 in the US, as of 20 June.
GlobalData is the parent company of Pharmaceutical Technology.
At a session on clinical research in the APAC region, Dr. Yooni Kim, the vice president of clinical services at Novotech, explained the pros of research in APAC geographies, while focusing on specific countries. For example, Kim highlighted that in Taiwan, regulators freely accept trial protocols that match standards from German, Japanese and French systems, amongst other countries. She said that this could help companies shorten timelines for clinical studies.
Kim also directed attention to South Korea, where the government has developed a national AI platform that integrates data from various healthcare institutions to support clinical trials. At a talk on AI in clinical research, Josep Bori, the research director of GlobalData鈥檚 Thematics division, highlighted AI鈥檚 potential to manage and engage with patients and manage healthcare data, amongst other things. Kim said South Korea鈥檚 platform is already helping companies with these tasks by monitoring clinical trials and recruiting patients for studies more efficiently. O鈥橲haughnessy鈥檚 2023 review highlighted a similar need for more data integration in the UK system, which was discussed on the second day of the conference.
Data integration
At the last keynote session of the event, O鈥橲haughnessy called attention to the need 鈥渢o take advantage of the NHS鈥檚 considerable data assets鈥�. At the same time, he highlighted that there is a lack of transparency around data collected during commercial clinical activity in the UK. In one of the related sessions, a clinical research professional in the audience, pointed out that while most research institutions and companies have independent data collection measures, they are unable to share it properly without a universal platform for the industry. Nonetheless, the former health minister shared hopes that the next government would prioritise the provision of 鈥渞eal-time data鈥� on the UK鈥檚 commercial clinical activity.
